721 related articles for article (PubMed ID: 31004638)
1. Regulation of neuronal microtubule dynamics by tau: Implications for tauopathies.
Venkatramani A; Panda D
Int J Biol Macromol; 2019 Jul; 133():473-483. PubMed ID: 31004638
[TBL] [Abstract][Full Text] [Related]
2. Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein.
Feuillette S; Miguel L; Frébourg T; Campion D; Lecourtois M
J Neurochem; 2010 May; 113(4):895-903. PubMed ID: 20193038
[TBL] [Abstract][Full Text] [Related]
3. Neuron-selective toxicity of tau peptide in a cell culture model of neurodegenerative tauopathy: essential role for aggregation in neurotoxicity.
Zhao K; Ippolito G; Wang L; Price V; Kim MH; Cornwell G; Fulenchek S; Breen GA; Goux WJ; D'Mello SR
J Neurosci Res; 2010 Nov; 88(15):3399-413. PubMed ID: 20882568
[TBL] [Abstract][Full Text] [Related]
4. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
[TBL] [Abstract][Full Text] [Related]
5. Embryonic stem cell-based modeling of tau pathology in human neurons.
Mertens J; Stüber K; Poppe D; Doerr J; Ladewig J; Brüstle O; Koch P
Am J Pathol; 2013 May; 182(5):1769-79. PubMed ID: 23499461
[TBL] [Abstract][Full Text] [Related]
6. Why Microtubules Should Be Considered as One of the Supplementary Targets for Designing Neurotherapeutics.
Das G; Ghosh S
ACS Chem Neurosci; 2019 Mar; 10(3):1118-1120. PubMed ID: 30657675
[TBL] [Abstract][Full Text] [Related]
7. [The microtubule-associated protein tau in neurodegenerative diseases. Tauopathies].
Sánchez MP; Alvarez-Tallada V; Avila J
Rev Neurol; 2001 Jul 16-31; 33(2):169-77. PubMed ID: 11562878
[TBL] [Abstract][Full Text] [Related]
8. Infantile tauopathies: Hemimegalencephaly; tuberous sclerosis complex; focal cortical dysplasia 2; ganglioglioma.
Sarnat HB; Flores-Sarnat L
Brain Dev; 2015 Jun; 37(6):553-62. PubMed ID: 25451314
[TBL] [Abstract][Full Text] [Related]
9. NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy.
Quraishe S; Cowan CM; Mudher A
Mol Psychiatry; 2013 Jul; 18(7):834-42. PubMed ID: 23587881
[TBL] [Abstract][Full Text] [Related]
10. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.
Brunden KR; Zhang B; Carroll J; Yao Y; Potuzak JS; Hogan AM; Iba M; James MJ; Xie SX; Ballatore C; Smith AB; Lee VM; Trojanowski JQ
J Neurosci; 2010 Oct; 30(41):13861-6. PubMed ID: 20943926
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of tau-induced neurodegeneration.
Iqbal K; Liu F; Gong CX; Alonso Adel C; Grundke-Iqbal I
Acta Neuropathol; 2009 Jul; 118(1):53-69. PubMed ID: 19184068
[TBL] [Abstract][Full Text] [Related]
12. Tauopathies and tau oligomers.
Takashima A
J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
[TBL] [Abstract][Full Text] [Related]
13. Role of tau protein in both physiological and pathological conditions.
Avila J; Lucas JJ; Perez M; Hernandez F
Physiol Rev; 2004 Apr; 84(2):361-84. PubMed ID: 15044677
[TBL] [Abstract][Full Text] [Related]
14. Increased acetylation of microtubules rescues human tau-induced microtubule defects and neuromuscular junction abnormalities in
Mao CX; Wen X; Jin S; Zhang YQ
Dis Model Mech; 2017 Oct; 10(10):1245-1252. PubMed ID: 28819043
[TBL] [Abstract][Full Text] [Related]
15. An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.
Carlomagno Y; Chung DC; Yue M; Castanedes-Casey M; Madden BJ; Dunmore J; Tong J; DeTure M; Dickson DW; Petrucelli L; Cook C
J Biol Chem; 2017 Sep; 292(37):15277-15286. PubMed ID: 28760828
[TBL] [Abstract][Full Text] [Related]
16. Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo.
Cowan CM; Bossing T; Page A; Shepherd D; Mudher A
Acta Neuropathol; 2010 Nov; 120(5):593-604. PubMed ID: 20617325
[TBL] [Abstract][Full Text] [Related]
17. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
Badiola N; Suárez-Calvet M; Lleó A
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
[TBL] [Abstract][Full Text] [Related]
18. Tau, microtubule dynamics, and axonal transport: New paradigms for neurodegenerative disease.
Cario A; Berger CL
Bioessays; 2023 Aug; 45(8):e2200138. PubMed ID: 37489532
[TBL] [Abstract][Full Text] [Related]
19. Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy.
Zhang B; Higuchi M; Yoshiyama Y; Ishihara T; Forman MS; Martinez D; Joyce S; Trojanowski JQ; Lee VM
J Neurosci; 2004 May; 24(19):4657-67. PubMed ID: 15140937
[TBL] [Abstract][Full Text] [Related]
20. Our Tau Tales from Normal to Pathological Behavior.
Alonso AD; Cohen LS
J Alzheimers Dis; 2018; 64(s1):S507-S516. PubMed ID: 29614672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
